A study tracking suicidal ideation across pregnancy and postpartum identified distinct trajectories and differences between the EPDS and PHQ-9, highlighting challenges in screening.
A new nonhormonal treatment targeting the neurokinin 3 receptor significantly reduced the frequency and severity of menopausal hot flashes in a Phase 2 trial.
A new meta-analysis examines ADHD medication use during pregnancy, finding reassuring results for most outcomes while identifying a possible small increase in cardiovascular malformations with methylphenidate.
Melatonin is widely used as a sleep aid, but what do we know about its safety during pregnancy? Explore the evidence, potential risks, and treatment options.
A small phase 2a trial of GH001, an investigational psychedelic compound, found a rapid reduction in postpartum depression symptoms. Larger studies are needed to assess safety and durability.
Perinatal OCD is common but often missed by depression-only screens. Adding perinatal-specific anxiety and OCD tools can improve detection and guide targeted treatment.
Parents of infants in the NICU face high rates of depression, anxiety, stress, and trauma. Are we doing enough to identify their needs—and provide meaningful mental health support?
In recognition of Suicide Prevention Awareness Month: A Message from Dr. Lee Cohen
In this North American cross-sectional study, higher exposure to early life adversities was associated with a higher lifetime prevalence of physician-diagnosed PCOS/PMOS. The findings add to growing evidence that childhood adversities may have lasting effects on reproductive health.
Women with PMOS have significantly higher rates of depression and anxiety. Routine screening and integrated care are essential for improving psychiatric and reproductive outcomes.
